(Q38110962)

29 August 2017

title

Emerging tyrosine kinase inhibitors for esophageal cancer (English)

1 reference

29 August 2017

Geoffrey Y Ku

1

1 reference

29 August 2017

David H Ilson

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

1 June 2013

1 reference

Expert Opinion on Emerging Drugs

29 August 2017

published in

1 reference

29 August 2017

volume

18

1 reference

29 August 2017

issue

2

1 reference

29 August 2017

page(s)

219-230

1 reference

29 August 2017

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Epidemiology of upper gastrointestinal malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Transhiatal esophagectomy: clinical experience and refinements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Sequential infusional 5-fluorouracil followed by concomitant radiation for tumors of the esophagus and gastroesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Neoadjuvant Cis-DDP in esophageal cancers: an experience at a regional cancer centre, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Carcinoma of the esophagus in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

A Pilot Phase II Study of Capecitabine in Advanced or Recurrent Gastric Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Growth factor receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Gefitinib--a novel targeted approach to treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Role of HER receptors family in development and differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

The HER-2/neu oncogene in tumors of the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

The biology of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Vascular endothelial growth factor in esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Molecular determinants in targeted therapy for esophageal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Phase II study of sunitinib as second-line treatment for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Novel agents on the horizon for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

MicroRNA expression profiles of esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Molecular biology of esophageal cancer in the genomics era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Molecular biology of upper gastrointestinal malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Oncogenic pathway combinations predict clinical prognosis in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

Amplification and over-expression of theEGFR anderbB-2 genes in human esophageal adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.805203

10.1517/14728214.2013.805203

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference